Lutein Bioavailability From Fresh and Dried Beverages

Bioavailability of Lutein From a Lutein-enriched Egg-yolk-beverage and Its Dried Re-suspended Versions.

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01400763

Acronym

METC-11/07

Enrollment

103

Registered

2011-07-22

Start date

2011-05-31

Completion date

2011-07-31

Last updated

2011-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Macular Pigment

Keywords

focus of study

Brief summary

Macular pigment is composed primarily of the xanthophylls lutein and zeaxanthin, which are members of the carotenoid family. Epidemiological evidence indicates that a higher intake of lutein and zeaxanthin is associated with a lower risk to develop age-related macular degeneration (AMD). The lipid matrix of an egg yolk is an excellent vehicle for the efficient absorption of dietary lutein and it is possible to increase the natural lutein concentration in an egg yolk. A fresh lutein-enriched egg yolk beverage has been produced using these lutein-enriched egg-yolks. However, this beverage has a limited shelf life of maximum three weeks. Drying this fresh beverage extents the shelf live, however, this should be without loosing its functional properties concerning lutein bioavailability. At WUR-FBR two types of drying procedures have been evaluated resulting in two different dried product formulations, which need to be tested. The question is, whether the lutein bioavailability is not affected by different drying procedures.

Interventions

DIETARY_SUPPLEMENTFresh lutein-enriched egg-yolk beverage

Fresh lutein-enriched egg-yolk beverage

DIETARY_SUPPLEMENTDried-1 lutein-enriched egg-yolk beverage

Dried-1 lutein-enriched egg-yolk beverage

DIETARY_SUPPLEMENTDried-2 lutein-enriched egg-yolk beverage

Dried-2 lutein-enriched egg-yolk beverage

DIETARY_SUPPLEMENTPlacebo beverage

Placebo beverage

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

SINGLE (Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 35 Years

Healthy volunteers

Yes

Inclusion criteria

* age 18-35 years * BMI 18-25 kg/m2 * body weight should be stable for ≥6 months (with no weight gain/loss \> 3 kg)

Exclusion criteria

* use of medication except incidental use of pain killers * pulmonary inhalation medication and except usage of the contraceptive pill * chronic diseases such as IBD or other stomach or bowel diseases * not willing to discontinue consumption of vitamin supplements * allergic to cow milk / dairy products/ eggs/ egg-rich products * vegetarians * smoking * pregnant or breastfeeding women * having donated blood (as blood donor) within 1 month prior to the screening * visit or planning to do so during the study * impossible or difficult venapuncture

Design outcomes

Primary

Measure	Time frame
Serum lutein concentration	six weeks after intervention

Secondary

Measure	Time frame
Serum lipid concentrations	six weeks after intervention

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026